ZURICH (Dow Jones)--Swiss pharmaceutical company Roche Holding AG (ROG.VX) said Friday it will start a new trial for Tarceva in lung cancer patients with a certain form of gene mutation, challenging a similar drug candidate from U.K.-rival AstraZeneca PLC (AZN) that got a positive European Union panel recommendation Thursday.
